FN2 Earnings Intelligence
Zoetis Inc. earnings overview
Latest Zoetis Inc. (ZTS) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Zoetis Inc.
Zoetis’s Q2 showed a mixed trajectory: livestock and Diagnostics remained strong, but U.S. Companion Animal weakness, competitive pricing, and lower FY2026 guidance weaken the near-term case for resilient, broad-based growth. The pipeline provides a longer-term support, but execution and market acceptance remain unproven.
Zoetis Inc.
Zoetis entered FY2026 with momentum from 6% organic growth in FY2025, but Q1 results revealed a sharp deterioration in its largest market. U.S. companion animal sales fell 8% as competitive pressure in dermatology and parasiticides intensified alongside rising price sensitivity among pet owners. International markets (10% organic) and livestock (12%) provided offsets but could not prevent flat overall organic revenue, an EPS miss of 4.4%, and a revenue miss of 1.7%. Management trimmed FY2026 guidance floors from 3%-5% to 2%-5% for revenue and from 3%-6% to 2%-6% for adjusted net income. The stock's 21% abnormal decline on report day, with an additional 9% drift, signals the market is pricing in sustained competitive and demand pressure rather than a transient dip.
Zoetis Inc.
Zoetis's FY2025 results support the view that diversified products, resilient Simparica demand, international growth, and the innovation pipeline can sustain growth into 2026. The case remains conditional on managing competition, pricing and volume, veterinary-visit trends, and product-launch execution.
Zoetis Inc.
The supplied analysis supports a cautiously constructive view of Zoetis's operating trajectory: Simparica, international markets, livestock demand, and the innovation pipeline provide support, while OA pain adoption, clinic visits, competition, and pricing remain important constraints.
Zoetis Inc.
The quarter supports a constructive but conditional view: resilient demand, strong core franchises, international livestock growth, and pipeline activity supported a guidance raise, while Librela adoption and competition remain important tests of whether that growth can persist.
Zoetis Inc.
The call supports a constructive but qualified view: resilient companion-animal demand, franchise strength and pipeline investment support continued growth, while competition, tariffs, adoption and regulatory timing are meaningful offsets.
Zoetis Inc.
The call provides evidence for a constructive one-year growth case: management highlighted expansion in parasiticides, osteoarthritis-pain biologics, alternative channels and the product pipeline. That case remains conditional because competition, pricing and volume mix, foreign exchange, regulatory scrutiny and the durability of margin improvement could offset franchise momentum.
Get the ZTS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.